## Clinical Context This patient is in remission after curative-intent treatment for stage III colorectal cancer. CEA is normal and imaging is negative. The question addresses the appropriate surveillance strategy. ## Surveillance Strategy in Colorectal Cancer Remission **Key Point:** Patients with stage II–III colorectal cancer in remission require structured surveillance for 5 years to detect recurrence early, when re-treatment may be curative. CEA and imaging (CT or colonoscopy) are the standard surveillance tools. **High-Yield:** ASCO and NCCN guidelines recommend: - **CEA monitoring**: Every 3–6 months for 5 years (more frequent in high-risk patients) - **Imaging**: CT chest/abdomen/pelvis every 6–12 months for 5 years (or every 3–6 months in high-risk stage III disease) - **Colonoscopy**: At 1 year post-op, then every 3–5 years if normal - **Rationale**: Early detection of resectable recurrence (locoregional or metastatic) improves survival ## Why Routine Surveillance is Correct 1. **Stage III disease**: Has significant recurrence risk (30–50% at 5 years); structured surveillance is standard of care. 2. **Normal CEA and imaging**: Does not eliminate recurrence risk; surveillance continues on schedule. 3. **5-year window**: Most recurrences occur within 5 years; surveillance is time-limited and evidence-based. 4. **Asymptomatic status**: Does not reduce need for surveillance; early recurrence is often detected before symptoms. ## Why Other Options Are Incorrect **Increased CEA frequency without indication:** CEA monitoring every month is excessive and not evidence-based. Monthly CEA does not improve outcomes and increases cost and patient anxiety. **Discharge without surveillance:** Inappropriate for stage III disease. Recurrence risk is substantial; surveillance detects resectable recurrence in ~10–15% of patients over 5 years. **Immediate colonoscopy:** Not indicated in asymptomatic patients with normal imaging. Colonoscopy is scheduled at 1 year post-op (to exclude anastomotic recurrence) and then every 3–5 years. This patient is only 18 months post-op; if colonoscopy was done at 1 year, the next is not due for 3–5 years. ```mermaid flowchart TD A[Stage III colorectal cancer in remission]:::outcome --> B{Asymptomatic + normal CEA + normal imaging?}:::decision B -->|Yes| C[Continue routine surveillance]:::action C --> D[CEA every 3-6 months]:::action C --> E[CT imaging every 6-12 months]:::action C --> F[Colonoscopy at 1 year post-op, then every 3-5 years]:::action D --> G[Duration: 5 years]:::action B -->|No: elevated CEA or imaging abnormality| H[Investigate for recurrence]:::urgent H --> I[Consider resection if resectable recurrence]:::action ``` ## Clinical Pearl **CEA as a surveillance tool:** CEA is most useful for detecting recurrence when serial measurements show a rising trend (even within the "normal" range), not as a single absolute value. A CEA of 2.1 ng/mL is normal, but if it rises to 5–10 ng/mL on subsequent measurements, recurrence must be excluded by imaging. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.